Use of biomarkers in clinical trials of alzheimer disease: From concept to application

Molecular Diagnosis and Therapy

Volumn 15, Issue 6, 2011, Pages 313-325

  Wu, Liyong ^a,b,c   Rosa Neto, Pedro ^a,b,d   Gauthier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimers disease; Biological marker targets; Biomarkers; Clinical trial design

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CARBON 11; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CLINICAL TRIAL (TOPIC); DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84555202769     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11595090-000000000-00000     Document Type: Review

References (133)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003 Aug; 60 (8): 1119-22 (Pubitemid 36975801)
2. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985 Jun; 82 (12): 4245-9 (Pubitemid 15053619)
3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992 Apr 10; 256 (5054): 184-5
4. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006 Jan-Mar; 20 (1): 6-15 (Pubitemid 44356888)
5. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 Aug; 6 (8): 734-46 (Pubitemid 47058377)
6. Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2005 Apr; 2 (2): 348-60 (Pubitemid 40471441)
7. Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 1994; 45: 435-46 (Pubitemid 24158173)
8. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010 Jul; 9 (7): 702-16
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 Jul 19; 297 (5580): 353-6 (Pubitemid 34790756)
10. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nuclear Med Biol 2007 Oct; 34 (7): 809-22 (Pubitemid 47503823)
11. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994 Jul; 13 (1): 45-53
12. Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006 Feb; 3 (1): 71-3
13. Hardy J, Duff K, Hardy KG, et al. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nature Neurosci 1998 Sep; 1 (5): 355-8
14. Feigin A. Evidence from biomarkers and surrogate endpoints. NeuroRx 2004 Jul; 1 (3): 323-30 (Pubitemid 46589361)
15. Jack Jr CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010 Jan; 9 (1): 119-28
16. Hampel H, Shen Y, Walsh DM, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exper Neurol 2010 Jun; 223 (2): 334-46
17. Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003 Feb 25; 60 (4): 652-6 (Pubitemid 36246085)
18. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005 Dec; 46 (12): 1959-72 (Pubitemid 46657441)
19. Jack Jr CR, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008 Mar; 131 (Pt 3): 665-80 (Pubitemid 351294719)
20. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir corrected F 18). J Nucl Med 2010 Jun; 51 (6): 913-20
21. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011 Jan 19; 305 (3): 275-83
22. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben ((1)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011 May; 10 (5): 424-35
23. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010 Sep; 68 (3): 319-29
24. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006 Nov; 129 (Pt 11): 3035-41 (Pubitemid 44684523)
25. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2009; 18 (2): 413-7
26. Jagust W, Reed B, Mungas D, et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007 Aug 28; 69 (9): 871-7 (Pubitemid 47329586)
27. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010 Jul 20; 75 (3): 230-8
28. Jack Jr CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010 Nov; 133 (11): 3336-48
29. Barnes J, Bartlett JW, van de Pol LA, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 2009 Nov; 30 (11): 1711-23
30. Stoub TR, Rogalski EJ, Leurgans S, et al. Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function. Neurobiol Aging 2010 Jul; 31 (7): 1089-98
31. Sluimer JD, van der Flier WM, Karas GB, etal. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 2008 Aug; 248 (2): 590-8
32. Habert MO, Horn JF, Sarazin M, et al. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiol Aging 2011 Jan; 32 (1): 15-23
33. Chao LL, Buckley ST, Kornak J, et al. ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord 2010 Jan-Mar; 24 (1): 19-27
34. Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mildcognitive impairment compared tonormal aging and AD. Neurology 2005 Aug 9; 65 (3): 404-11 (Pubitemid 41099803)
35. Greicius MD, Srivastava G, Reiss AL, et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004 Mar 30; 101 (13): 4637-42 (Pubitemid 38437463)
36. Lorenzi M, Beltramello A, Mercuri NB, et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs Aging 2011 Mar 1; 28 (3): 205-17
37. Kantarci K, Jack Jr CR, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000 Jul 25; 55 (2): 210-7 (Pubitemid 30604620)
38. Salat DH, Tuch DS, van der Kouwe AJ, et al. White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging 2010 Feb; 31 (2): 244-56
39. Swardfager W, Lanctot K, Rothenburg L, et al. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010 Nov 15; 68 (10): 930-41
40. Yokokura M, Mori N, Yagi S, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nuclear Med Mol Imag 2011 Feb; 38 (2): 343-51
41. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009 Jan 6; 72 (1): 56-62
42. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008 Jul 8; 71 (2): 85-92
43. Herholz K, Weisenbach S, Zundorf G, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. NeuroImage 2004 Jan; 21 (1): 136-43 (Pubitemid 38115004)
44. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment dueto Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimer's Dementia 2011 May; 7 (3): 270-9
45. Nordberg A. Amyloid imaging in Alzheimer's disease. Neuropsychologia 2008; 46 (6): 1636-41
46. Nordberg A. Molecular imaging markers in clinical trials in Alzheimer s disease. J Nutr Health Aging 2009 Apr; 13 (4): 346-7
47. Forsberg A, Almkvist O, Engler H, et al. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010 Feb; 7 (1): 56-66
48. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008 Oct; 29 (10): 1456-65
49. Morris JC, Roe CM, Grant EA, et al. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009 Dec; 66 (12): 1469-75
50. Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009 Nov; 50 (11): 1887-94
51. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and ADsubjects: diagnostic discrimination and cognitive correlations. Neurology 2009 Jul 28; 73 (4): 287-93
52. Schoonenboom NS, van der Flier WM, Blankenstein MA, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008 May; 29 (5): 669-75 (Pubitemid 351400823)
53. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003 Dec; 60 (12): 1696-702 (Pubitemid 37521622)
54. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006 Mar; 59 (3): 512-9 (Pubitemid 43358072)
55. Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of {beta}-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011 Sep; 68 (9): 1137-44
56. Jagust WJ, Landau SM, Shaw LM, etal. Relationships between biomarkersin aging and dementia. Neurology 2009 Oct 13; 73 (15): 1193-9
57. Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 2011 Mar; 7 (2): 133-41
58. Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004 Mar; 61 (3): 378-84 (Pubitemid 38327357)
59. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009 May 28; 360 (22): 2302-9
60. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003 Oct; 2 (10): 605-13 (Pubitemid 37162569)
61. Mattsson N, Blennow K, Zetterberg H. CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 2009 Oct; 1180: 28-35
62. Hampel H, Burger K, Teipel SJ, et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008 Jan; 4 (1): 38-48
63. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007 Dec; 80 (2): S160-7 (Pubitemid 351799343)
64. Minoshima S,GiordaniB, Berent S, etal. Metabolic reductioninthe posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997 Jul; 42 (1): 85-94 (Pubitemid 27304784)
65. Hampel H, Wilcock G, Andrieu S, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011 Dec; 95 (4): 579-93
66. Killiany RJ, Moss MB, Albert MS, et al. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993 Sep; 50 (9): 949-54 (Pubitemid 23275123)
67. Vemuri P, Wiste HJ, Weigand SD, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010 Jul 13; 75 (2): 143-51
68. Jack Jr CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009 May; 132 (Pt 5): 1355-65
69. Fox NC, Scahill RI, Crum WR, et al. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999 May 12; 52 (8): 1687-9 (Pubitemid 29220648)
70. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008 Sep 2; 71 (10): 743-9
71. Hua X, Leow AD, Parikshak N, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. NeuroImage 2008 Nov 15; 43 (3): 458-69
72. Prince SE, Woo S, Doraiswamy PM, et al. Functional MRI in the early diagnosis of Alzheimer's disease: is it time to refocus? Expert Rev Neurother 2008 Feb; 8 (2): 169-75 (Pubitemid 351281106)
73. Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 2008 Aug; 29 (8): 1204-17 (Pubitemid 351822413)
74. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009; 21 (1): 117-28
75. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004 Mar 23; 62 (6): 925-31 (Pubitemid 38435780)
76. Petersen RC, Jack Jr CR. Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment. Clin Pharmacol Ther 2009 Oct; 86 (4): 438-41
77. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimer Dementia 2011 May; 7 (3): 280-92
78. Sunderland T, Hampel H, Takeda M, et al. Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatric Psychiatry Neurol 2006 Sep; 19 (3): 172-9 (Pubitemid 44154857)
79. Chertkow H, Black S. Imaging biomarkers and their role in dementia clinical trials. Can J Neurol Sci 2007 Mar; 34 Suppl. 1: S77-83 (Pubitemid 46761781)
80. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer's disease perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004 Mar; 111 (3): 247-72 (Pubitemid 38316604)
81. Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exper Gerontol 2010 Jan; 45 (1): 5-14
82. Vellas B, Andrieu S, Sampaio C, et al. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2008 May; 7 (5): 436-50 (Pubitemid 351509424)
83. Vellas B, Andrieu S, Sampaio C, et al. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2007 Jan; 6 (1): 56-62 (Pubitemid 44880273)
84. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998 Mar-Apr; 19 (2): 109-16
85. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009 Apr; 65 (4): 403-13
86. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011 May; 7 (3): e13-44
87. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004 Apr; 1 (2): 189-95 (Pubitemid 46604746)
88. Coley N, Andrieu S, Delrieu J, et al. Biomarkers in Alzheimer's disease: not yet surrogate endpoints. Ann N Y Acad Sci 2009 Oct; 1180: 119-24
89. Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer's disease? Alzheimers Dement 2009 Nov; 5 (6): 489-91
90. Mintun MA, Larossa GN, Sheline YI, et al. 11CPIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006 Aug 8; 67 (3): 446-52 (Pubitemid 44214969)
91. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007 Nov; 130 (Pt 11): 2837-44 (Pubitemid 350033975)
92. Andreasen N, Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr Med Chem 2008; 15 (8): 766-71 (Pubitemid 351516792)
93. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009 Sep 8; 73 (10): 754-60
94. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand 11CPIB uptake is increased in mild cognitive impairment. Neurology 2007 May 8; 68 (19): 1603-6 (Pubitemid 46717985)
95. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006 Nov; 129 (Pt 11): 2856-66 (Pubitemid 44684508)
96. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003 Apr 23-30; 289 (16): 2094-103 (Pubitemid 37430211)
97. Mulder C, Verwey NA, van der Flier WM, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010 Feb; 56 (2): 248-53
98. van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009 Mar 24; 72 (12): 1056-61
99. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009 Jul; 8 (7): 619-27
100. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006 Mar; 5 (3): 228-34 (Pubitemid 43238346)
101. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009 Jul 22; 302 (4): 385-93
102. Wallin AK, Blennow K, Zetterberg H, et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010 May 11; 74 (19): 1531-7
103. Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009 Oct 27; 73 (17): 1353-8
104. Langbaum JB, Chen K, Lee W, etal. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage 2009 May 1; 45 (4): 1107-16
105. Teipel SJ, Drzezga A, Bartenstein P, et al. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology 2006 Jul; 187 (1): 86-94 (Pubitemid 43876920)
106. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebocontrolled trial of the effects of donepezil on neuronal markers and hippo-campal volumes in Alzheimer's disease. Am J Psychiatry 2003 Nov; 160 (11): 2003-11 (Pubitemid 39619638)
107. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006 Mar; 27 (3): 394-401 (Pubitemid 43185324)
108. Braak H, BraakE. Evolution of neuronal changesinthe course of Alzheimer's disease. J Neural Transmission 1998; 53: 127-40 (Pubitemid 28361774)
109. Querbes O, Aubry F, Pariente J, et al. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain 2009 Aug; 132 (Pt 8): 2036-47
110. Jack Jr CR, Shiung MM, Gunter JL, etal. Comparisonofdifferent MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004 Feb 24; 62 (4): 591-600 (Pubitemid 38252801)
111. Jack Jr CR, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005 Oct 25; 65 (8): 1227-31 (Pubitemid 41508215)
112. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010 Nov; 9 (11): 1118-27
113. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement 2011 May; 7 (3): 263-9
114. Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005 Apr; 162 (4): 676-82 (Pubitemid 40489128)
115. Wang L, Harms MP, Staggs JM, et al. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Arch Neurol 2010 Jan; 67 (1): 99-106
116. Tateno M, Kobayashi S, Utsumi K, et al. Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer's disease by using an automated program, 3DSRT. Neuroradiology 2008 Aug; 50 (8): 723-7
117. Cummings JL, Doody R, Clark C.Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007 Oct 16; 69 (16): 1622-34 (Pubitemid 350287147)
118. Aisen PS. Amyloid-based therapeutics: findings translated into novel treatments. CNS Spectrums 2008 Oct; 13 (10 Suppl. 16): 36-8
119. Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement 2009 Sep; 5 (5): 406-18
120. Lyketsos CG, Szekely CA, Mielke MM, et al. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr 2008 Oct; 20 (5): 871-89
121. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010 Apr; 9 (4): 363-72
122. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009 Dec 15; 73 (24): 2061-70
123. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008 Sep; 7 (9): 779-86
124. Zhou B, Teramukai S, Yoshimura K, et al. Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis 2009; 18 (1): 89-102
125. Blennow K. Biomarkers in Alzheimer's disease drug development. Nature Med 2010 Nov; 16 (11): 1218-22
126. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005 May 10; 64 (9): 1563-72 (Pubitemid 40617692)
127. Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Current Alzheimer Res 2009 Apr; 6 (2): 144-51
128. Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007 Nov 27; 4 (11): e338
129. Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005 Oct; 76 (10): 1348-54 (Pubitemid 41360969)
130. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trialsin early (predementia) AD. Neurology 2011 Jan 18; 76 (3): 280-6
131. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica 2011 May; 121 (5): 597-609
132. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011 Jan 6; 3 (1): 1
133. Laske C, LeyheT, StranskyE, etal. Identificationofablood-based biomarker panel for classification of Alzheimer's disease. Int J Neuropsychopharmacol 2011 Oct; 14 (9): 1147-55